Table 3.
Activities of BC-3781 and comparator antimicrobial agents against bacterial pathogens causing predominantly ABSSSI and other infections
| Species (no. tested) and antimicrobial agent | MIC50 (μg/ml) | MIC90 (μg/ml) | Range (μg/ml) | CLSI %S/%Ra | EUCAST %S/%Ra |
|---|---|---|---|---|---|
| S. aureus (5,527) | |||||
| BC-3781 | 0.12 | 0.12 | 0.015–>16 | ||
| Clindamycin | ≤0.25 | >2 | ≤0.25–>2 | 82.0/17.8 | 81.4/18.0 |
| Daptomycin | 0.25 | 0.5 | ≤0.06–2 | >99.9/− | >99.9/<0.1 |
| Doxycycline | 0.12 | 0.25 | ≤0.06–>8 | 97.9/0.4 | 95.3/3.1 |
| Erythromycin | 2 | >4 | ≤0.25–>4 | 49.2/49.1 | 49.2/50.0 |
| Levofloxacin | ≤0.5 | >4 | ≤0.5–>4 | 63.4/35.3 | 63.4/35.3 |
| Linezolid | 1 | 1 | ≤0.12–4 | 100.0/0.0 | 100.0/0.0 |
| Oxacillin | 0.5 | >2 | ≤0.25–>2 | 57.1/42.9 | 57.1/42.9 |
| Quinupristin-dalfopristin | ≤0.5 | ≤0.5 | ≤0.5–>4 | 99.9/0.1 | 99.9/0.1 |
| Tigecyclineb | 0.12 | 0.25 | ≤0.03–0.5 | 100.0/− | 100.0/0.0 |
| Trimethoprim-sulfamethoxazole | ≤0.5 | ≤0.5 | ≤0.5–>4 | 97.7/2.3 | 97.7/2.0 |
| Vancomycin | 1 | 1 | 0.25–2 | 100.0/0.0 | 100.0/0.0 |
| MRSA (2,370) | |||||
| BC-3781 | 0.12 | 0.25 | 0.015–4 | ||
| Clindamycin | ≤0.25 | >2 | ≤0.25–>2 | 63.5/36.4 | 63.1/36.5 |
| Daptomycin | 0.25 | 0.5 | ≤0.06–2 | 99.9/− | 99.9/0.1 |
| Doxycycline | 0.12 | 1 | ≤0.06–>8 | 96.2/0.8 | 93.0/5.4 |
| Erythromycin | >4 | >4 | ≤0.25–>4 | 15.0/84.1 | 15.0/84.6 |
| Levofloxacin | >4 | >4 | ≤0.5–>4 | 26.8/71.2 | 26.8/71.2 |
| Linezolid | 1 | 1 | ≤0.12–2 | 100.0/0.0 | 100.0/0.0 |
| Oxacillin | >2 | >2 | >2 | 0.0/100.0 | 0.0/100.0 |
| Quinupristin-dalfopristin | ≤0.5 | ≤0.5 | ≤0.5–>4 | 99.9/0.1 | 99.9/0.1 |
| Tigecyclineb | 0.12 | 0.25 | ≤0.03–0.5 | 100.0/− | 100.0/0.0 |
| Trimethoprim-sulfamethoxazole | ≤0.5 | ≤0.5 | ≤0.5–>4 | 95.8/4.2 | 95.8/3.8 |
| Vancomycin | 1 | 1 | 0.25–2 | 100.0/0.0 | 100.0/0.0 |
| Beta-hemolytic Streptococcus spp. (763) | |||||
| BC-3781 | 0.03 | 0.03 | ≤0.008–16 | ||
| Clindamycin | ≤0.25 | >2 | ≤0.25–>2 | 87.3/12.6 | 87.4/12.6 |
| Daptomycin | ≤0.06 | 0.25 | ≤0.06–0.5 | 100.0/− | 100.0/0.0 |
| Doxycycline | 0.25 | 8 | ≤0.06–>8 | 51.1/48.1 | |
| Erythromycin | ≤0.25 | >4 | ≤0.25–>4 | 76.4/22.7 | 76.4/22.7 |
| Levofloxacin | ≤0.5 | 1 | ≤0.5–>4 | 99.2/0.4 | 95.8/0.8 |
| Linezolid | 1 | 1 | 0.5–2 | 100.0/− | 100.0/0.0 |
| Penicillin | ≤0.03 | 0.06 | ≤0.03–0.12 | 100.0/− | 100.0/0.0 |
| Quinupristin-dalfopristin | ≤0.5 | ≤0.5 | ≤0.5–1 | 100.0/0.0 | |
| Tigecyclineb | ≤0.03 | 0.06 | ≤0.03–0.25 | 100.0/− | 100.0/0.0 |
| Trimethoprim-sulfamethoxazole | ≤0.5 | ≤0.5 | ≤0.5–>4 | 98.4/1.4 | |
| Vancomycin | 0.25 | 0.5 | ≤0.12–1 | 100.0/− | 100.0/0.0 |
| S. pyogenes, group A streptococci (267) | |||||
| BC-3781 | 0.03 | 0.03 | ≤0.008–0.06 | ||
| Clindamycin | ≤0.25 | ≤0.25 | ≤0.25–>2 | 95.9/4.1 | 95.9/4.1 |
| Daptomycin | ≤0.06 | ≤0.06 | ≤0.06–0.25 | 100.0/− | 100.0/0.0 |
| Doxycycline | 0.12 | 8 | ≤0.06–>8 | 85.4/13.5 | |
| Erythromycin | ≤0.25 | ≤0.25 | ≤0.25–>4 | 90.6/9.4 | 90.6/9.4 |
| Levofloxacin | ≤0.5 | 1 | ≤0.5–>4 | 98.5/0.7 | 91.8/1.5 |
| Linezolid | 1 | 1 | 0.5–1 | 100.0/− | 100.0/0.0 |
| Penicillin | ≤0.03 | ≤0.03 | ≤0.03–0.12 | 100.0/− | 100.0/0.0 |
| Quinupristin-dalfopristin | ≤0.5 | ≤0.5 | ≤0.5 | 100.0/0.0 | |
| Tigecyclineb | ≤0.03 | 0.06 | ≤0.03–0.12 | 100.0/− | 100.0/0.0 |
| Trimethoprim-sulfamethoxazole | ≤0.5 | ≤0.5 | ≤0.5–>4 | 97.4/2.2 | |
| Vancomycin | 0.25 | 0.5 | ≤0.12–0.5 | 100.0/− | 100.0/0.0 |
| S. agalactiae, group B streptococci (334) | |||||
| BC-3781 | 0.03 | 0.03 | ≤0.008–16 | ||
| Clindamycin | ≤0.25 | >2 | ≤0.25–>2 | 78.4/21.3 | 78.7/21.3 |
| Daptomycin | 0.12 | 0.25 | ≤0.06–0.5 | 100.0/− | 100.0/0.0 |
| Doxycycline | 8 | 8 | ≤0.06–>8 | 16.2/83.2 | |
| Erythromycin | ≤0.25 | >4 | ≤0.25–>4 | 63.8/34.4 | 63.8/34.4 |
| Levofloxacin | ≤0.5 | 1 | ≤0.5–>4 | 99.7/0.3 | 97.6/0.3 |
| Linezolid | 1 | 1 | 0.5–1 | 100.0/− | 100.0/0.0 |
| Penicillin | ≤0.03 | 0.06 | ≤0.03–0.06 | 100.0/− | 100.0/0.0 |
| Quinupristin-dalfopristin | ≤0.5 | ≤0.5 | ≤0.5–1 | 100.0/0.0 | |
| Tigecyclineb | ≤0.03 | 0.06 | ≤0.03–0.25 | 100.0/− | 100.0/0.0 |
| Trimethoprim-sulfamethoxazole | ≤0.5 | ≤0.5 | ≤0.5–>4 | 99.7/0.3 | |
| Vancomycin | 0.5 | 0.5 | 0.25–1 | 100.0/− | 100.0/0.0 |
| Viridans group Streptococcus spp.c (245) | |||||
| BC-3781 | 0.12 | 0.5 | ≤0.008–2 | ||
| Clindamycin | ≤0.25 | ≤0.25 | ≤0.25–>2 | 90.2/8.6 | 91.4/8.6 |
| Daptomycin | 0.25 | 0.5 | ≤0.06–1 | 100.0/− | |
| Doxycycline | 0.25 | >8 | ≤0.06–>8 | ||
| Erythromycin | ≤0.25 | >4 | ≤0.25–>4 | 51.8/46.1 | |
| Linezolid | 1 | 1 | 0.25–2 | 100.0/− | |
| Levofloxacin | 1 | 2 | ≤0.5–>4 | 94.7/4.5 | |
| Penicillin | 0.06 | 0.5 | ≤0.03–>4 | 75.1/3.7 | 86.5/3.7 |
| Quinupristin-dalfopristin | ≤0.5 | 1 | ≤0.5–1 | 100.0/0.0 | |
| Tigecyclineb | ≤0.03 | 0.06 | ≤0.03–0.12 | 100.0/− | |
| Trimethoprim-sulfamethoxazole | ≤0.5 | 2 | ≤0.5–>4 | ||
| Vancomycin | 0.5 | 0.5 | ≤0.12–1 | 100.0/− | 100.0/0.0 |
| E. faecium (536) | |||||
| BC-3781 | 0.12 | 4 | 0.015–>16 | ||
| Ampicillin | >8 | >8 | ≤1–>8 | 5.8/94.2 | 5.8/94.2 |
| Daptomycin | 2 | 2 | ≤0.06–4 | 100.0/− | |
| Doxycycline | 4 | >8 | ≤0.06–>8 | 55.6/32.8 | |
| Erythromycin | >4 | >4 | ≤0.25–>4 | 3.4/87.1 | |
| Levofloxacin | >4 | >4 | ≤0.5–>4 | 4.7/93.7 | |
| Linezolid | 1 | 1 | 0.5–>8 | 98.7/0.9 | 99.1/0.9 |
| Quinupristin-dalfopristin | ≤0.5 | 2 | ≤0.5–>4 | 88.2/4.7 | 88.2/0.2 |
| Tigecyclineb | 0.12 | 0.25 | ≤0.03–>4 | 99.1/− | 99.1/0.2 |
| Vancomycin | >16 | >16 | 0.25–>16 | 43.3/56.3 | 43.3/56.7 |
a
%S, percentage of susceptible organisms; %R, percentage of resistant organisms. Criteria were as published by the CLSI (2012) and EUCAST (2011) (25, 26).
b
U.S. FDA breakpoints were applied (Tygacil label [27]).
c
Includes the following species (isolate numbers): S. anginosus (22), S. bovis (9), S. canis (2), S. constellatus (6), S. gallolyticus (11), S. gordonii (5), S. intermedius (2), S. milleri (5), S. mitis (64), S. mutans (4), S. oralis (16), S. parasanguinis (7), S. salivarius (20), S. sanguinis (13), S. vestibularis (2), and unspecified viridans group streptococci (57).